“We are scaling the ZEVASKYN launch to meet patient needs,” said Vish Seshadri, Chief Executive Officer of Abeona. “We have strong and growing patient demand. Despite a one-quarter shift in patient starts, we remain steadfast in our 2026 launch goals. Our conviction is built on our expanding treatment site network and powerful momentum from the patient and caregiver community.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- Abeona Therapeutics announces permanent J-Code for ZEVASKYN
- Abeona Therapeutics appoints Gow as SVP, Head of Clinical Development
- Abeona Therapeutics announces ABO-503 gene therapy for XLRS selected by FDA
- Abeona, Children’s Hospital Colorado activate newest QTC for ZEVASKYN